However, because APRIL can still bind to TACI and BCMA, belimumab treatment is more commonly used to inhibit naive B lymphocytes (28), resulting in a relatively weak effect on plasma cells and a less rapid response to therapy for life-threatening thrombocytopenia. The gene discussed is TNFRSF13B; the disease is Thrombocytopenia.